Sanofi
INSULIN GLARGINE/LIXISENATIDE FIXED RATIO FORMULATION
Last updated:
Abstract:
The present invention refers to a pharmaceutical composition comprising (a) lixisenatide or/and a pharmaceutically acceptable salt thereof, and (b) insulin glargine or/and a pharmaceutically acceptable salt thereof, wherein the compound (b) and compound (a) are present in a fixed ratio.
Status:
Application
Type:
Utility
Filling date:
3 May 2021
Issue date:
3 Feb 2022